LGVN
LGVN
NASDAQ · Biotechnology

Longeveron Inc-A

$0.70
-0.01 (-0.97%)
As of Jun 30, 10:53 PM ET ·
Financial Highlights (FY 2026)
Revenue
2.15M
Net Income
-40,815,073
Gross Margin
67.0%
Profit Margin
-1,893.6%
Rev Growth
-0.6%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 67.0% 67.0% 43.6% 43.6%
Operating Margin -1,942.2% -1,748.0% -2.2% -2.6%
Profit Margin -1,893.6% -1,798.9% -2.4% -2.8%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 2.15M 2.17M 3.54M 3.93M
Gross Profit 1.44M 1.45M 1.54M 1.71M
Operating Income -41,854,021 -37,907,435 -77,362 -100,425
Net Income -40,815,073 -36,966,454 -86,327 -108,943
Gross Margin 67.0% 67.0% 43.6% 43.6%
Operating Margin -1,942.2% -1,748.0% -2.2% -2.6%
Profit Margin -1,893.6% -1,798.9% -2.4% -2.8%
Rev Growth -0.6% -0.6% +8.8% +5.3%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 4.00M 4.40M
Total Equity 6.27M 5.45M
D/E Ratio 0.64 0.81
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -39,658,588 -37,914,520 -134,724 -147,370
Free Cash Flow -61,141 -91,187